Cargando…

Fidaxomicin Inhibits Spore Production in Clostridium difficile

Fidaxomicin (FDX) is a novel antimicrobial agent with narrow-spectrum and potent bactericidal activity against Clostridium difficile. In recent clinical trials, FDX was superior to vancomycin in preventing recurrences of C. difficile infection. A possible mechanism of reducing recurrence may be thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Babakhani, Farah, Bouillaut, Laurent, Gomez, Abraham, Sears, Pamela, Nguyen, Ly, Sonenshein, Abraham L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388029/ https://www.ncbi.nlm.nih.gov/pubmed/22752866 http://dx.doi.org/10.1093/cid/cis453

Ejemplares similares

Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
por: Nerandzic, Michelle M., et al.
Publicado: (2012)

Antimicrobial Activities of Fidaxomicin
por: Goldstein, Ellie J. C., et al.
Publicado: (2012)

Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
por: Sears, Pamela, et al.
Publicado: (2012)

Carvacrol and trans-Cinnamaldehyde Reduce Clostridium difficile Toxin Production and Cytotoxicity in Vitro
por: Mooyottu, Shankumar, et al.
Publicado: (2014)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Metabolism of Bile Salts in Mice Influences Spore Germination in Clostridium difficile
por: Giel, Jennifer L., et al.
Publicado: (2010)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
por: Artsimovitch, Irina, et al.
Publicado: (2012)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production
por: Chilton, Caroline H., et al.
Publicado: (2016)

Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile
por: Eyre, David W., et al.
Publicado: (2014)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea
por: Eiland, Edward H., et al.
Publicado: (2015)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
por: Mullane, Kathleen M., et al.
Publicado: (2011)

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
por: van Engen, Anke, et al.
Publicado: (2015)

Clostridium difficile Spore-Macrophage Interactions: Spore Survival
por: Paredes-Sabja, Daniel, et al.
Publicado: (2012)

Spore Formation and Toxin Production in Clostridium difficile Biofilms
por: Semenyuk, Ekaterina G., et al.
Publicado: (2014)

Fidaxomicin for Clostridium difficile-Associated Diarrhoea: Epidemiological Method for Estimation of Warranted Price
por: Sclar, David Alexander, et al.
Publicado: (2012)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly
por: Dhruv, Samyak, et al.
Publicado: (2020)

Aerial Dissemination of Clostridium difficile spores
por: Roberts, Katherine, et al.
Publicado: (2008)

Muricholic Acids Inhibit Clostridium difficile Spore Germination and Growth
por: Francis, Michael B., et al.
Publicado: (2013)

Fidaxomicin for the Treatment of Clostridium Difficile Infection in the Pediatric Population - Not Quite So Soon Yet
por: Daniels, Tanya, et al.
Publicado: (2011)

Fate of Ingested Clostridium difficile Spores in Mice
por: Howerton, Amber, et al.
Publicado: (2013)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

Burden of Clostridium difficile on the Healthcare System
por: Dubberke, Erik R., et al.
Publicado: (2012)

Novel FR-900493 Analogues That Inhibit the Outgrowth of Clostridium difficile Spores
por: Mitachi, Katsuhiko, et al.
Publicado: (2018)

A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
por: Mullane, Kathleen M, et al.
Publicado: (2019)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses
por: Cornely, Oliver A., et al.
Publicado: (2019)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Current Status of Clostridium difficile Infection Epidemiology
por: Lessa, Fernanda C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ado9qhpes83nijd46g6jfc8gev